Research output incl. preprints · 74 publications

Publications

Explore peer-reviewed research and preprints from KRI researchers and collaborators, reflecting the breadth of scientific discovery and translational research across the Institute.

2026202520242023202220212020201920182017201620152014201320122003 – 2011

2026

4 papers
  1. Ref · 2026 / 01Endothelin receptor blockade potentiates adoptive T cell and CAR T cell therapies

    Papagregoriou C, Mpekris F, Yoon J, Kastrappis G, Lytridou AA, Thrasyvoulou M, Symeonidis K, Pitsillidou C, Neophytou C, Panagi M, Voutouri C, Iakovou M, Gregoriou G, Stylianopoulos T, Maciocia P, Costeas P, Demetriou P.

    bioRxiv. 2026. doi: 10.64898/2026.09.02.748239.

  2. Ref · 2026 / 02Discovery of Causative Genetic Variants in Patients with Congenital and/or Developmental Anomalies by Exome Sequencing

    Theodosiou A, Kousoulidou L, Papaevripidou I, Aristidou C, Alexandrou A, Hadjipanteli A, Votsi C, Tomazou M, Menelaou S, Efstathiou D, Ioannou Y, Athanasiou E, Papamichael E, Christophidou-Anastasiadou V, Ourani S, Evangelidou P, Tanteles GA, Sismani C.

    Genes (Basel). 2026 Jul 24;17(8):863. doi: 10.3390/genes17080863. PMID: 42650056; PMCID: PMC13512218.

  3. Ref · 2026 / 03Population genetic variation characterised through serial independent pool-seq: the Cyprus Genome Project

    Antoniades A, Chi J, Brown C, Vogazianos P, Charalambous E, Vrachnos D, Aristodimou A, Miltiadous A, Papaloizou A, Koumouli A, Gerasimou P, Kyprianou Y, Costeas P.

    Sci Rep. 2026 Mar 19;16(1):14215. doi: 10.1038/s41598-026-44707-x. PMID: 41857113; PMCID: PMC13139603.

  4. Ref · 2026 / 04Case Report: Novel ASAP1::BRAF fusion in a young adult with low-grade temporal lobe glioma

    Gerasimou P, Vrachnos D, Kyprianou Y, Elpidoforou A, Miltiadous A, Mitsidou A, Nicolaou K, Shianiou G, Zartila C, Ioannou C, Christofi A, Georgiou E, Avgousti C, Kanezou M, Johnson M, Papanastassiou V, Oxinou C, Theodorou M, Shiarli AM, Antoniades A, Chi J, Costeas P.

    Front Oncol. 2026 Jan 23;16:1763047. doi: 10.3389/fonc.2026.1763047. PMID: 41659712; PMCID: PMC12878647.

2025

9 papers
  1. Ref · 2025 / 01CD2 costimulation strength: A key regulator of T cell function and anti-tumor immunity that is epigenetically regulated

    Demetriou P, Iakovou M, Gregoriou G, Vrachnos D, Chi J, Tamamouna V, Stavrou G, Constantinou S, Papanastasiou V, Antoniades A, Costeas P.

    iScience. 2025 Nov 10;28(12):113977. doi: 10.1016/j.isci.2025.113977. PMID: 41377664; PMCID: PMC12688680.

  2. Ref · 2025 / 02Investigating the "Dark" Genome: First Report of Partington Syndrome in Cyprus

    Aristidou C, Theodosiou A, Antoniou P, Alexandrou A, Papaevripidou I, Kousoulidou L, Koutsou P, Georghiou A, Delikurt T, Spanou E, Salameh N, Evangelidou P, Christodoulou K, Verloes A, Christophidou-Anastasiadou V, Tanteles GA, Sismani C.

    Genes (Basel). 2025 Oct 15;16(10):1224. doi: 10.3390/genes16101224. PMID: 41153441; PMCID: PMC12564775.

  3. Ref · 2025 / 03The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)

    Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Jong MM, Links TP, Brems H, Aerden M, Brunet J, Lleuger-Pujol R, Hüneburg R, Aretz S, Colas C, Villy MC, Woodward ER, Evans DG, Bosch DGM, Donze SH, Foretová L, Blatnik A, Leter EM, Tischkowitz M, Jahn A, de Putter R, Dupont J, Briskemyr S, Steinke-Lange V, Baldassarri M, Anastasiadou VC, Irmejs A, Oliveira C, van der Post RS, Mensenkamp AR, Tesi B, Mu N, Benusiglio PR, Gerasimenko A, Innella G, Turchetti D, Houdayer C, Branchaud M, Høberg Vetti H, Tveit Haavind M, Balmaña J, Torres M, Genuardi M, Panfili A, Jørgensen K, Mæhle L, Hoogerbrugge N, Vos JR.

    Genet Med. 2025 Oct;27(10):101467. doi: 10.1016/j.gim.2025.101467. Epub 2025 May 24. PMID: 40433764.

  4. Ref · 2025 / 04Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis

    McLoughlin MA, Cheloor Kovilakam S, Dunn WG, Gu M, Tobin J, Pershad Y, Williams N, Leongamornlert D, Dawson K, Bond L, Marando L, Wen S, Wilson R, Valenzano G, Symeonidou V, Rak J, Damaskou A, Gozdecka M, Liu X, Barcena C, Nomdedeu J, Costeas P, Dimitriou ID, Fiorillo E, Orrù V, de Almeida JG, McKerrell T, Cullen M, Mohorianu I, Foukaneli T, Warren AJ, Wong C, Follows G, Godfrey AL, Gudgin E, Cucca F, McKinney E, Baxter EJ, Gerstung M, Mitchell J, Wiseman D, Bick AG, Fabre M, Quiros PM, Nangalia J, Kar S, Vassiliou GS.

    Nat Genet. 2025 Sep;57(9):2215-2225. doi: 10.1038/s41588-025-02296-x. Epub 2025 Aug 28. PMID: 40877435; PMCID: PMC12425810.

  5. Ref · 2025 / 05Cancer prognosis and treatment results in patients with PTEN Hamartoma Tumour Syndrome (PHTS)-a European cohort study

    Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Putter R, Brems H, Van Daele SH, Anastasiadou VC, Foretová L, Benusiglio PR, Gerasimenko A, Colas C, Villy MC, Houdayer C, Branchaud M, Hüneburg R, Aretz S, Jahn A, Steinke-Lange V, Innella G, Turchetti D, Barili V, Genuardi M, Panfili A, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Donze SH, van der Post RS, Mensenkamp AR, Westdorp H, Høberg-Vetti H, Tveit Haavind M, Jørgensen K, Mæhle L, Briskemyr S, Garcia JD, Blatnik A, Balmaña J, Torres M, Brunet J, Lleuger-Pujol R, Tham E, Tischkowitz M, Evans DG, Hyder Z, Hoogerbrugge N, Vos JR.

    BJC Rep. 2025 Jun 4;3(1):42. doi: 10.1038/s44276-025-00157-y. PMID: 40468016; PMCID: PMC12137667.

  6. Ref · 2025 / 06YME1L1 Dysfunction Associated With 3-Methylglutaconic Aciduria

    Demetriadou A, Grafakou O, Georgiou T, Burska D, Malekkou A, Krizova J, Paramera E, Mavrikiou G, Dionysiou M, Theodosiou A, Sismani C, Anastasiadou V, Ioannou I, Papakonstantinou E, Hansikova H, Drousiotou A, Petrou PP.

    J Inherit Metab Dis. 2025 May;48(3):e70029. doi: 10.1002/jimd.70029. PMID: 40255048; PMCID: PMC12010149.

  7. Ref · 2025 / 07Dysbiosis in the Gut Microbiome of Pembrolizumab-Treated Non-Small Lung Cancer Patients Compared to Healthy Controls Characterized Through Opportunistic Sampling

    Charalambous H, Brown C, Vogazianos P, Katsaounou K, Nikolaou E, Stylianou I, Papageorgiou E, Vraxnos D, Aristodimou A, Chi J, Costeas P, Shammas C, Apidianakis Y, Antoniades A.

    Thorac Cancer. 2025 May;16(9):e70075. doi: 10.1111/1759-7714.70075. PMID: 40356191; PMCID: PMC12069221.

  8. Ref · 2025 / 08Fetal genetic factors in pregnancy loss: Insights from a meta-analysis and effectiveness of whole exome sequencing

    Hadjipanteli A, Theodosiou A, Papaevripidou I, Alexandrou A, Salameh N, Evangelidou P, Tomazou M, Mavrides A, Fasouliotis S, Anastasiou G, Stavroulis A, Agathokleous N, Agathokleous M, Tsangarides S, Kallikas I, Kakoullis K, Frakala S, Oxinou C, Marnerides A, Athanasiou E, Ourani S, Anastasiadou VC, Tanteles G, Kousoulidou L, Sismani C.

    PLoS One. 2025 Feb 25;20(2):e0319052. doi: 10.1371/journal.pone.0319052. PMID: 39999070; PMCID: PMC11856309.

  9. Ref · 2025 / 09Insulin-Like Growth Factor-1 (IGF-1) Deficiency and Metabolic-Dysfunction-Associated Steatotic Liver Disease in a Young Patient

    Flourou C, Azina C, Georgiou G, Anastasiadou V.

    Cureus. 2025 Jan 8;17(1):e77146. doi: 10.7759/cureus.77146. PMID: 39781288; PMCID: PMC11709139.

2024

6 papers
  1. Ref · 2024 / 01Seminoma in 46, XY Gonadal Dysgenesis: Rare Presentation and Review of the Literature

    Adra M, Nakanishi H, Papachristodoulou E, Karaoli E, Gerasimou P, Miltiadous A, Nicolaou K, Loizou L, Skordis N.

    J Clin Res Pediatr Endocrinol. 2024 Dec 4;16(4):495-500. doi: 10.4274/jcrpe.galenos.2023.2023-12-11. Epub 2023 Apr 19. PMID: 37074092; PMCID: PMC11629731.

  2. Ref · 2024 / 02Single-Cell Analysis of Bone Marrow CD8+ T Cells in Myeloid Neoplasms Reveals Pathways Associated with Disease Progression and Response to Treatment with Azacitidine

    Tasis A, Papaioannou NE, Grigoriou M, Paschalidis N, Loukogiannaki C, Filia A, Katsiki K, Lamprianidou E, Papadopoulos V, Rimpa CM, Chatzigeorgiou A, Kourtzelis I, Gerasimou P, Kyprianou I, Costeas P, Liakopoulos P, Liapis K, Kolovos P, Chavakis T, Alissafi T, Kotsianidis I, Mitroulis I.

    Cancer Res Commun. 2024 Dec 1;4(12):3067-3083. doi: 10.1158/2767-9764.CRC-24-0310. PMID: 39485042; PMCID: PMC11616010.

  3. Ref · 2024 / 03Dynamics and spatial organization of Kv1.3 at the immunological synapse of human CD4+ T cells

    Capera J, Jainarayanan A, Navarro-Pérez M, Valvo S, Demetriou P, Depoil D, Estadella I, Kvalvaag A, Felce JH, Felipe A, Dustin ML.

    Biophys J. 2024 Aug 6;123(15):2271-2281. doi: 10.1016/j.bpj.2023.08.011. Epub 2023 Aug 18. PMID: 37596785; PMCID: PMC11331042.

  4. Ref · 2024 / 04PDE10A Mutation as an Emerging Cause of Childhood-Onset Hyperkinetic Movement Disorders: A Review of All Published Cases

    Kalampokini S, Xiromerisiou G, Bargiotas P, Anastasiadou VC, Costeas P, Hadjigeorgiou GM.

    Neuropediatrics. 2024 Aug;55(4):217-223. doi: 10.1055/a-2281-1822. Epub 2024 Mar 5. PMID: 38442915.

  5. Ref · 2024 / 05Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS)

    Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, Mensenkamp AR, Brems H, de Putter R, Anastasiadou VC, Villy MC, Jahn A, Steinke-Lange V, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Høberg-Vetti H, Tveit Haavind M, Jørgensen K, Mæhle L, Blatnik A, Brunet J, Darder E, Tham E, Hoogerbrugge N, Vos JR.

    Cancers (Basel). 2024 Feb 27;16(5):953. doi: 10.3390/cancers16050953. PMID: 38473316; PMCID: PMC10930780.

  6. Ref · 2024 / 06Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy

    Zhou Q, Zhang J, Zhang J, Liang S, Cai D, Xiao H, Zhu Y, Xiang W, Rodrigues-Lima F, Chi J, Guidez F, Wang L.

    Biol Direct. 2024 Jan 4;19(1):6. doi: 10.1186/s13062-023-00451-0. PMID: 38178263; PMCID: PMC10768477.

2023

5 papers
  1. Ref · 2023 / 01Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses

    Lysandrou M, Stamou P, Kefala D, Pierides C, Kyriakou M, Savvopoulos N, Christofi P, Papadopoulou A, Yannaki E, Costeas P, Spyridonidis A.

    Front Immunol. 2023 Sep 27;14:1235661. doi: 10.3389/fimmu.2023.1235661. PMID: 37828996; PMCID: PMC10565652.

  2. Ref · 2023 / 02GAA variants associated with reduced enzymatic activity but lack of Pompe-related symptoms, incidentally identified by exome sequencing

    Malekkou A, Theodosiou A, Alexandrou A, Papaevripidou I, Sismani C, Jacobs EH, Ruijter GJG, Anastasiadou V, Ourani S, Athanasiou E, Drousiotou A, Grafakou O, Petrou PP.

    Mol Genet Metab Rep. 2023 Aug 7;36:100997. doi: 10.1016/j.ymgmr.2023.100997. PMID: 37600231; PMCID: PMC10433214.

  3. Ref · 2023 / 03Fecal Microbiota and Associated Volatile Organic Compounds Distinguishing No-Adenoma from High-Risk Colon Adenoma Adults

    Katsaounou K, Yiannakou D, Nikolaou E, Brown C, Vogazianos P, Aristodimou A, Chi J, Costeas P, Agapiou A, Frangou E, Tsiaoussis G, Potamitis G, Antoniades A, Shammas C, Apidianakis Y.

    Metabolites. 2023 Jul 4;13(7):819. doi: 10.3390/metabo13070819. PMID: 37512526; PMCID: PMC10383435.

  4. Ref · 2023 / 04Twin hearts-minimally invasive mitral valve repair in twin sisters with mitral annular disjunction and Loeys-Dietz syndrome: a case series

    Ioannou S, Shiakos G, Ntoskas T, Papasavvas E, Anastasiadi V, Loizides NB, Mavrommatis P, Tzanavaros I.

    J Surg Case Rep. 2023 Jun 17;2023(6):rjad344. doi: 10.1093/jscr/rjad344. PMID: 37337538; PMCID: PMC10276975.

  5. Ref · 2023 / 05Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome

    Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, Høberg-Vetti H, Tveit Haavind M, Innella G, Turchetti D, Aretz S, Spier I, Tischkowitz M, Jahn A, Links TP, Olderode-Berends MJW, Blatnik A, Leter EM, Evans DG, Woodward ER, Steinke-Lange V, Anastasiadou VC, Colas C, Villy MC, Benusiglio PR, Gerasimenko A, Barili V, Branchaud M, Houdayer C, Tesi B, Yazicioglu MO, van der Post RS, Schuurs-Hoeijmakers JHM; PTEN Study Group; Vos JR.

    J Natl Cancer Inst. 2023 Jan 10;115(1):93-103. doi: 10.1093/jnci/djac188. PMID: 36171661.

2022

8 papers
  1. Ref · 2022 / 01Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort

    Hendricks LAJ, Hoogerbrugge N, Venselaar H, Aretz S, Spier I, Legius E, Brems H, de Putter R, Claes KBM, Evans DG, Woodward ER, Genuardi M, Brugnoletti F, van Ierland Y, Dijke K, Tham E, Tesi B, Schuurs-Hoeijmakers JHM, Branchaud M, Salvador H, Jahn A, Schnaiter S, Anastasiadou VC, Brunet J, Oliveira C, Roht L, Blatnik A, Irmejs A; PTEN Study Group; Mensenkamp AR, Vos JR.

    Eur J Med Genet. 2022 Dec;65(12):104632. doi: 10.1016/j.ejmg.2022.104632. Epub 2022 Oct 18. PMID: 36270489.

  2. Ref · 2022 / 02Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention

    Tamamouna V, Pavlou E, Neophytou CM, Papageorgis P, Costeas P.

    Int J Mol Sci. 2022 Nov 11;23(22):13931. doi: 10.3390/ijms232213931. PMID: 36430404; PMCID: PMC9698240.

  3. Ref · 2022 / 03Genetic Markers for Thrombophilia and Cardiovascular Disease Associated with Multiple Sclerosis

    Hadjiagapiou MS, Krashias G, Deeba E, Kallis G, Papaloizou A, Costeas P, Christodoulou C, Pantzaris M, Lambrianides A.

    Biomedicines. 2022 Oct 21;10(10):2665. doi: 10.3390/biomedicines10102665. PMID: 36289926; PMCID: PMC9599167.

  4. Ref · 2022 / 04A de novo SFMBT1 pathogenic variant identified in a boy with Poland syndrome

    Miltiadous A, Demetriou P, Kyriakou M, Gerasimou P, Herodotou G, Elpidoforou A, Kyprianou Y, Iacovou M, Chi J, Costeas P, Tanteles GA.

    Cold Spring Harb Mol Case Stud. 2022 Apr 28;8(3):a006168. doi: 10.1101/mcs.a006168. PMID: 35483874; PMCID: PMC9059785.

  5. Ref · 2022 / 05Polymeric micelles effectively reprogram the tumor microenvironment to potentiate nano-immunotherapy in mouse breast cancer models.

    Panagi M, Mpekris F, Chen P, Voutouri C, Nakagawa Y, Martin JD, Hiroi T, Hashimoto H, Demetriou P, Pierides C, Samuel R, Stylianou A, Michael C, Fukushima S, Georgiou P, Papageorgis P, Papaphilippou PC, Koumas L, Costeas P, Ishii G, Kojima M, Kataoka K, Cabral H, Stylianopoulos T.

    Nat Commun. 2022 Nov 22;13(1):7165. doi: 10.1038/s41467-022-34744-1. PMID: 36418896; PMCID: PMC9684407.

  6. Ref · 2022 / 06The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients.

    Dunn WG, Gu MS, Fabre MA, Cooper J, Nomdedeu JF, Koumas L, Nicolaou K, Chi J, Costeas P, Vassiliou GS.

    Ann Hematol. 2022 Feb.

  7. Ref · 2022 / 07Pharmacological activation of the C5a receptor leads to stimulation of the beta-adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer's disease.

    Fella E, Papacharalambous R, Kynigopoulos D, Ioannou M, Derua R, Christodoulou C, Stylianou M, Karaiskos C, Kagiavas A, Gerasimou P, Pierides C, Kyriakou M, Koumas L, Costeas P, Panagiotou E.

    Frontiers in Immunology. Aug 2022.

  8. Ref · 2022 / 08Racial/Ethnic Disparities on the Risk of Second Malignant Neoplasm Among Hodgkin Lymphoma Survivors.

    Xiao H, He J, Liang S, Cai D, Zhou Q, Liu L, Yan X, Chi J, Xiao Q, Wang L.

    Front Oncol. 2022 Jan 24;11:790891.

2021

7 papers
  1. Ref · 2021 / 01Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.

    Yankova E, Blackaby W, Albertella M, Rak J, Braekeleer ED, Tsagkogeorga G, Pilka ES, Aspris D, Leggate D, Hendrick AG, Webster NA, Andrews B, Fosbeary R, Guest P, Irigoyen N, Eleftheriou M, Gozdecka M, Dias JML, Bannister AJ, Vick B, Jeremias I, Vassiliou GS, Rausch O, Tzelepis K, Kouzarides T.

    Nature. 2021 May.

  2. Ref · 2021 / 02The N6-methyladenosine RNA modification in acute myeloid leukemia.

    Yankova E, Aspris D, Tzelepis K.

    Curr Opin Hematol. 2021 Mar 1.

  3. Ref · 2021 / 03Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.

    Yu T, Chi J, Wang L.

    Hematology. 2021 Dec;26(1):848-859.

  4. Ref · 2021 / 04Network Pharmacology and Experimental Validation Reveal the Effects of Chidamide Combined With Aspirin on Acute Myeloid Leukemia-Myelodysplastic Syndrome Cells Through PI3K/AKT Pathway.

    Liang S, Zhou X, Cai D, Rodrigues-Lima F, Chi J, Wang L.

    Front Cell Dev Biol. 2021 Sep 9;9:685954.

  5. Ref · 2021 / 05METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation.

    Orellana EA, Liu Q, Yankova E, Pirouz M, Braekeleer ED, Zhang W, Lim J, Aspris D, Sendinc E, Garyfallos DA, Gu M, Ali R, Gutierrez A, Mikutis S, Bernardes GJL, Fischer ES, Bradley A, Vassiliou GS, Slack FJ, Tzelepis K, Gregory RI.

    Mol Cell. 2021 Aug 19;81(16):3323-3338.

  6. Ref · 2021 / 06Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.

    Koukoulias K, Papadopoulou A, Kouimtzidis A, Papayanni PG, Papaloizou A, Sotiropoulos D, Yiangou M, Costeas P, Anagnostopoulos A, Yannaki E, Kaloyannidis P.

    Br J Haematol. 2021 Jul;194(1):158-167.

  7. Ref · 2021 / 07Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

    Agathangelidis A, Chatzidimitriou A, et al. (incl. Costeas P), Stamatopoulos K.

    Blood. 2021 Mar 11;137(10):1365-1376.

2020

6 papers
  1. Ref · 2020 / 01Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis.

    Mpekris F, Panagi M, Voutouri C, Martin JD, Samuel R, Takahashi S, Gotohda N, Suzuki T, Papageorgis P, Demetriou P, Pierides C, Koumas L, Costeas P, Kojima M, Ishii G, Constantinidou A, Kataoka K, Cabral H, Stylianopoulos T.

    Adv Sci (Weinh). 2020 Dec 13;8(3):2001917. doi: 10.1002/advs.202001917. PMID: 33552852; PMCID: PMC7856901.

  2. Ref · 2020 / 02meCLICK-Seq, a Substrate-Hijacking and RNA Degradation Strategy for the Study of RNA Methylation.

    Mikutis S, Gu M, Sendinc E, Hazemi ME, Kiely-Collins H, Aspris D, Vassiliou GS, Shi Y, Tzelepis K, Bernardes GJL.

    ACS Cent Sci. 2020 Dec 23.

  3. Ref · 2020 / 03The Role of Tumour-Associated Myeloid Cells in Modulating Cancer Therapy.

    Neophytou MC, Pierides C, Christodoulou MI, Costeas P, Kyriakou TC, Papageorgis P.

    Front Oncol. 2020 Jun 9. Review article.

  4. Ref · 2020 / 04TGF-beta inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.

    Panagi M, Voutouri C, Mpekris F, Papageorgis P, Martin MR, Martin JD, Demetriou P, Pierides C, Polydorou C, Stylianou A, Louca M, Koumas L, Costeas P, Kataoka K, Cabral H, Stylianopoulos T.

    Theranostics. 2020 Jan 12;10(4):1910-1922. doi: 10.7150/thno.36936. PMID: 32042344; PMCID: PMC6993226.

  5. Ref · 2020 / 05The rare DNA ligase IV syndrome: A case report.

    Gerasimou P, Koumas L, Miltiadous A, Kyprianou I, Chi J, Gavrielidou R, Socratous E, Loizou L, Papachristodoulou E, Karaoli E, Loizos A, Anastasiadou V, Costeas P.

    Human Pathology: Case Reports, Vol. 22, Nov. 2020.

  6. Ref · 2020 / 06HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia.

    Cell Death Dis. 2020 Jun 30;11(6):492.

2019

1 paper
  1. Ref · 2019 / 01C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar Aβ amyloid and preserves memory in a mouse model of familial Alzheimer's disease.

    Panayiotou E, Fella E, Andreou S, Papacharalambous R, Gerasimou P, Costeas P, Angeli S, Kousiappa I, Papacostas S, Kyriakides T.

    PLoS One. 2019 Dec 6;14(12):e0225417.

2018

3 papers
  1. Ref · 2018 / 01SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

    Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS.

    Nat Commun. 2018 Dec 19;9(1):5378.

  2. Ref · 2018 / 02MicroRNA 143 increases cell apoptosis in myelodysplastic syndrome through the Fas/FasL pathway both in vitro and in vivo.

    Cui J, Wei C, Deng L, Kuang X, Zhang Z, Pierides C, Chi J, Wang L.

    Int J Oncol. 2018 Nov;53(5):2191-2199.

  3. Ref · 2018 / 03Combined effect of glutamine at position 70 of HLA-DRB1 and alanine at position 57 of HLA-DQB1 in type 1 diabetes: An epitope analysis.

    Gerasimou P, Nicolaidou V, Skordis N, Picolos M, Monos D, Costeas PA.

    PLoS One. 2018 Mar 1;13(3):e0193684.

2017

4 papers
  1. Ref · 2017 / 01JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.

    McKerrell T, Park N, Chi J, Collord G, Moreno T, Ponstingl H, Dias J, Gerasimou P, Melanthiou K, Prokopiou C, Antoniades M, Varela I, Costeas PA, Vassiliou GS.

    Blood Adv. 2017 Jun 12;1(14):968-971.

  2. Ref · 2017 / 02Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease.

    Stamou P, Marioli D, Patmanidi AL, Sgourou A, Vittoraki A, Theofani E, Pierides C, Taraviras S, Costeas PA, Spyridonidis A.

    Cytotherapy. 2017 Apr;19(4):521-530.

  3. Ref · 2017 / 03HLA-G variability and haplotypes detected by massively parallel sequencing procedures in the geographically distinct population samples of Brazil and Cyprus.

    Castelli EC, Gerasimou P, Paz MA, Ramalho J, Porto IOP, Lima THA, Souza AS, Veiga-Castelli LC, Collares CVA, Donadi EA, Mendes-Junior CT, Costeas P.

    Mol Immunol. 2017 Mar;83:115-126.

  4. Ref · 2017 / 04Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

    Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

    Leukemia. 2017 Mar;31(3):593-601.

2016

4 papers
  1. Ref · 2016 / 01Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries

    Pana ZD, Seidel D, Skiada A, Groll AH, Petrikkos G, Cornely OA, Roilides E; Collaborators of Zygomyco.net and/or FungiScope™ Registries*.

    BMC Infect Dis. 2016 Nov 10;16(1):667. doi: 10.1186/s12879-016-2005-1. PMID: 27832748; PMCID: PMC5105268.

  2. Ref · 2016 / 02SET-NUP214 rearrangement in isolation is insufficient to induce leukemia: a single center experience

    Prokopiou C, Koumas S, Neokleous N, Seimeni O, Barmpouti A.

    Leuk Lymphoma. 2016 Feb;57(2):451-452. doi: 10.3109/10428194.2015.1049169. Epub 2015 Jun 18. PMID: 25956045.

  3. Ref · 2016 / 03Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

    McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS.

    Blood. 2016 Jul 7;128(1):e1-9.

  4. Ref · 2016 / 04HLA-G 14-bp polymorphism affects the age of onset in Type I Diabetes Mellitus.

    Gerasimou P, Skordis N, Picolos M, Spyridonidis A, Costeas P.

    Int J Immunogenet. 2016 Jun;43(3):135-42.

2015

5 papers
  1. Ref · 2015 / 01SPARC ectopic overexpression inhibits growth and promotes programmed cell death in acute myeloid leukemia transformed from myelodysplastic syndrome cells, alone and in combination with Ara-C treatment

    Nian Q, Chi J, Xiao Q, Wei C, Costeas P, Yang Z, Liu L, Wang L.

    Oncol Rep. 2015 Sep;34(3):1406-14. doi: 10.3892/or.2015.4114. Epub 2015 Jul 8. PMID: 26165695.

  2. Ref · 2015 / 02Gene expression changes in HLA mismatched mixed lymphocyte cultures reveal genes associated with allorecognition.

    Nicolaidou V, Stylianou C, Koumas L, Vassiliou GS, Bodman-Smith KB, Costeas P.

    Tissue Antigens. 2015 Apr;85(4):267-77.

  3. Ref · 2015 / 03Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring.

    Chi J, Manoloukos M, Pierides C, Nicolaidou V, Nicolaou K, Kleopa M, Vassiliou G, Costeas P.

    Ann Hematol. 2015 Mar;94(3):399-408.

  4. Ref · 2015 / 04The EUTOS population-based registry: Incidence and clinical characteristics of 2,904 CML patients in twenty European Countries.

    Leukemia. 2015 Mar 18.

  5. Ref · 2015 / 05cDNA synthesis for BCR-ABL1 detection at the MMR level: the importance of using the appropriate kit.

    Chi J, Pierides C, Mitsidou A, Miltiadou A, Gerasimou P, Costeas P.

    Biol Proced Online. 2015 Feb 9;17(1):4.

2014

2 papers
  1. Ref · 2014 / 01A sensitive detection method for MPLW515L or MPLW515K mutation in myeloproliferative disorders.

    Chi J, Pierides C, Mitsidou A, Miltiadou A, Gerasimou P, Nicolaou K, Costeas P.

    European Journal of Experimental Biology, 2014, 4(5):33-36.

  2. Ref · 2014 / 02Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol.

    Bolli N, Manes N, McKerrell T, Chi J, Park N, Gundem G, Quail MA, Sathiaseelan V, Herman B, Crawley C, Craig JI, Conte N, Grove C, Papaemmanuil E, Campbell PJ, Varela I, Costeas P, Vassiliou GS.

    Haematologica. 2015 Feb;100(2):214-22.

2013

2 papers
  1. Ref · 2013 / 01Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis.

    Chi J, Nicolaou KA, Nicolaidou V, Koumas L, Mitsidou A, Pierides C, Manoloukos M, Barbouti K, Melanthiou F, Prokopiou C, Vassiliou GS, Costeas P.

    Leukemia. 2014 May;28(5):1152-4.

  2. Ref · 2013 / 02Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture.

    Conte N, Varela I, Grove C, Manes N, Yusa K, Moreno T, Segonds-Pichon A, Bench A, Gudgin E, Herman B, Bolli N, Ellis P, Haddad D, Costeas P, Rad R, Scott M, Huntly B, Bradley A, Vassiliou GS.

    Leukemia. 2013 Sep;27(9):1820-5.

2012

3 papers
  1. Ref · 2012 / 01Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells.

    Nicolaou KA, Liapis V, Evdokiou A, Constantinou C, Magiatis P, Skaltsounis AL, Koumas L, Costeas PA, Constantinou AI.

    Biochem Biophys Res Commun. 2012 Aug 17;425(1):76-82.

  2. Ref · 2012 / 02Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: a case control study.

    Eftychiou C, Antoniades L, Makri L, Koumas L, Costeas PA, Kyriakou E, Nicolaides E, Papadogiannis D.

    Hellenic J Cardiol. 2012 May-Jun;53(3):189-94.

  3. Ref · 2012 / 03Donors as research subjects: a challenge.

    King R, Schmidt AH, Costeas P, Egeland T.

    Bone Marrow Transplant. 2012 Apr;47(4):605-6.

2003 – 2011

5 papers
  1. Ref · 2003–2011 / 01Unrelated hematopoietic stem cell donors as research subjects.

    King RJ, Confer DL, Greinix HT, Halter J, Horowitz M, Schmidt AH, Costeas P, Shaw B, Egeland T; Ethics and Clinical Working Groups of World Marrow Donor Association.

    Bone Marrow Transplant. 2011 Jan;46(1):10-3.

  2. Ref · 2003–2011 / 02Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health.

    Sacchi N, Costeas P, Hartwell L, Hurley CK, Raffoux C, Rosenmayr A, Greinix H; Quality Assurance and Clinical Working Groups of the World Marrow Donor Association.

    Bone Marrow Transplant. 2008 Jul;42(1):9-14.

  3. Ref · 2003–2011 / 03Th2/Th3 cytokine genotypes are associated with pregnancy loss.

    Costeas PA, Koumouli A, Giantsiou-Kyriakou A, Papaloizou A, Koumas L.

    Hum Immunol. 2004 Feb;65(2):135-41.

  4. Ref · 2003–2011 / 04Genetic assessment of cardiovascular risk factors in the Greek Cypriot population.

    Koumas L, Costeas PA, Papaloizou A, Giantsiou-Kyriakou A.

    Thromb Res. 2003;112(3):143-6.

  5. Ref · 2003–2011 / 05Cytokine polymorphism frequencies in the Greek Cypriot population.

    Costeas PA, Koumas L, Koumouli A, Kyriakou-Giantsiou A, Papaloizou A.

    Eur J Immunogenet. 2003 Oct;30(5):341-3.